<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-DZ91LAUY</identifier><date>2015</date><creator>Boc, Marko</creator><creator>Ebert Moltara, Maja</creator><creator>Mesti, Tanja</creator><creator>Ocvirk, Janja</creator><creator>Reberšek, Martina</creator><relation>documents/doc/D/URN_NBN_SI_doc-DZ91LAUY_001.pdf</relation><relation>documents/doc/D/URN_NBN_SI_doc-DZ91LAUY_001.txt</relation><format format_type="issue">1</format><format format_type="volume">49</format><format format_type="type">article</format><format format_type="extent">str. 80-85, VI</format><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID">1813371</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-DZ91LAUY</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">bevacizumab</subject><subject language_type_id="slv">irinotecan</subject><subject language_type_id="slv">maligni gliomi</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="eng">recurrent malignant glioma</subject><subject language_type_id="slv">sistemska terapija</subject><subject language_type_id="eng">systemic therapy</subject><title>Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience</title></Record>